Escalé-Besa A., Fuster-Casanovas A., Börve A., Yélamos O., Fustà-Novell X., Rafat M.E., Marin-Gomez F.X., Vidal-Alaball J.. Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study. Jmir Research Protocols. 2022; 11(8)DOI:10.2196/37531. PMID:. IF:(Q/D).

Bechman K., Cook E.S., Dand N., Yiu Z.Z.N., Tsakok T., Meynell F., Coker B., Vincent A., Bachelez H., Barbosa I., Brown M.A., Capon F., Contreras C.R., De La Cruz C., Meglio P.D., Gisondi P., Jullien D., Kelly J., Lambert J., Lancelot C., Langan S.M., Mason K.J., McAteer H., Moorhead L., Naldi L., Norton S., Puig L., Spuls P.I., Torres T., Urmston D., Vesty A., Warren R.B., Waweru H., Weinman J., Griffiths C.E.M., Barker J.N., Smith C.H., Galloway J.B., Mahil S.K.. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2)DOI:10.1111/bjd.21042. PMID:35104366. IF:10.300(Q1/1D).

Zachariae C., Mrowietz U., Strodl Andersen J., Puig L.. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4)DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2.500(Q2/5D).

Sánchez-Rodríguez G., Puig L.. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6)DOI:10.1016/j.piel.2021.06.020. PMID:. IF:(Q/D).

Van Huizen A.M., Menting S.P., Gyulai R., Iversen L., Van Der Kraaij G.E., Middelkamp-Hup M.A., Warren R.B., Spuls P.I., Schejtman A.A., Egeberg A., Firooz A., Kumar A.S., Oakley A., Foulkes A., Ramos A.M.C., Fougerousse A.-C., Carija A., Akman-Karakas A., Horváth B., Fábos B., Matlock B.H., Claréus B.W., Castro C., Ferrándiz C., Correa C.C., Marchesi C., Goujon C., Gonzalez C., Maldonado-García C., Hong C.-H., Griffiths C.E.M., Vestergaard C., Echeverría C.M., De La Cruz C., Conrad C., Törocsik D., Drvar D.L., Balak D., Jullien D., Appelen D., Kim D.H., De Jong E.M.G.J., El Gamal E., Laffitte E., Mahé E., Sonkoly E., Colombo E.P., Vilarrasa E., Willaert F., Novoa F.D., Handjani F., Valenzuela F., Vílchez-Márquez F., Gonzalez G.O., Krisztián G., Damiani G., Krnjevic-Pezic G., Pellerano G., Carretero G., Hunter H.J.A., Riad H., Oon H.H., Boonen H.P.J., Moussa I.O., García-Doval I., Csányi I., Brajac I., Turchin I., Grozdev I., Weinberg J.M., Nicolopoulos J., Wells J., Lambert J.L.W., Ingram J.R., Prinz J.C., De Souza Sittart J.A., Sanchez J.L., Hsiao J.P.-F., Castro-Ayarza J.R., Maul J.-T., Van Den Reek J.M.P.A., Trcko K., Barber K., Reich K., Gebauer K.A., Khobzei K., Maul L.V., Massari L.P., Fardet L., Le Cleach L., Misery L., Chandrashekar L., Muresanu L.I., Lecluse L., Skov L., Frez M.L., Babic L.T., Puig L., Gomez L.C., Ramam M., Dutil M., El-Sayed M.H., Olszewska M., Schram M.E., Franco M.D., Llamas-Velasco M., Gonçalo M., Velásquez-Lopera M.M., Abad M.E., De Oliveira M.D.F.S.P., Seyger M.M.B., Kaštelan M., Rademaker M., Sikora M., Lebwohl M., Wiseman M.C., Ferran M., Van Doorn M., Danespazhooh M., Bylaite-Bucinskiene M., Gooderham M.J., Polic M.V., De Rie M.A., Zheng M., Gómez-Flores M., Salleras I Redonnet M., Silverberg N.B., Doss N., Yawalkar N., Chosidow O., Zargari O., De La Cueva P., Fernandez-Peñas P., Cárdenas Rojas P.J., Gisondi P., Grewal P., Sator P., Luna P.C., Félix P.A.O., Varela P., Holló P., Cetkovska P., Calzavara-Pinton P., Ghislain P.-D., Araujo R.R., Romiti R., Kui R., Ceovic R., Vender R., Lafuente-Urrez R.F., Del-Río R., Gulin S.J., Handa S., Mahil S.K., Kolalapudi S.A., Marrón S.E., Azimi S.Z., Janmohamed S.R., Da Cruz Costa S.A., Choon S.E., Urbancek S., Ayanlowo O., Margasin S.M., Wong T.-W., Mälkönen T., Hurtová T., Reciné T.R., Huldt-Nystrøm T., Torres T., Liu T.-Y., Leonidze T., Sharma V.K., Weightman W., Gulliver W., Veldkamp W.. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5)DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10.900(Q1/1D).

Papp K.A., Thoning H., Gerdes S., Megna M., Brandi H., Jablonski Bernasconi M.Y., Yélamos O.. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(7)DOI:10.1080/09546634.2022.2095330. PMID:35875991. IF:2.900(Q2/4D).

Puig L., Daudén E., Cuervas-Mons M., Novella C., Guisado C.. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39DOI:10.1111/jdv.19403. PMID:37567861. IF:8.000(Q1/1D).

Armario-Hita JC, Carrascosa JM, Flórez Á, Herranz P, Pereyra-Rodríguez JJ, Serra-Baldrich E, Silvestre JF, Comellas M, Isidoro O, Ortiz de Frutos FJ. Pruritus and Pain Constitute the Main Negative Impact of Atopic Dermatitis From the Patient's Perspective: A Systematic Review. Dermatitis. 2024; 35(3)DOI:10.1089/derm.2023.0163. PMID:37751176. IF:3.200(Q1/2D).